It is possible that the α9 neutralization that suppressed synovium activation and yielded positive results in the mouse model is not sufficient by itself to treat human RA where direct modulation of immune-pathway activation through additional targets may also be required. This evidence concerns the gene IGKV1D-22 and rheumatoid arthritis.